GSTO1-1 upregulation has been reported in various cancers, including pancreatic cancer [52], esophageal adenocarcinoma [53,54], colorectal cancer [55], and ovarian cancer, where the upregulation has been associated with drug resistance [24,56]. This evidence concerns the gene GSTO1 and ovarian cancer.